Workflow
120万天价治疗费有解?体内CAR-T有望降本至1/10

Core Viewpoint - The article discusses the promising advancements in "in vivo CAR-T" technology, which aims to make cancer treatment more accessible and affordable, potentially reducing costs to one-tenth of traditional methods and improving patient outcomes [3][4][5]. Group 1: Current Challenges in CAR-T Therapy - Traditional CAR-T therapy involves extracting a patient's T cells, modifying them in a lab, and reinfusing them, which is time-consuming (1-3 weeks) and costly (over 1 million yuan per treatment) [3][4]. - The complexity of the production process limits the widespread adoption of CAR-T technology, making it a "sky-high treatment" for ordinary people [3][4]. Group 2: Advancements in In Vivo CAR-T Technology - In vivo CAR-T technology allows for direct injection of carriers (like viruses or lipid nanoparticles) that modify T cells within the patient's body, eliminating the need for cell extraction [4]. - This method is expected to significantly reduce treatment costs and improve accessibility, with potential costs dropping to one-tenth of traditional CAR-T therapy [4][5]. - The treatment can show effects as quickly as three days after one or two intravenous injections, addressing the urgent needs of patients who cannot wait for traditional methods [4][5]. Group 3: Industry Implications - The shift towards in vivo CAR-T technology is attracting attention from both capital and industry, with multiple Chinese companies exploring this field [4]. - The maturation of in vivo CAR-T technology could lead to a future where patients receive effective cell therapy through simple injections, broadening the range of treatable diseases [5].